Literature DB >> 12845642

Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells.

Jacek Wojciechowski1, Marcel Horky, Marieta Gueorguieva, Józefa Wesierska-Gadek.   

Abstract

The aim of our study was to explore the antiproliferative and pro-apoptotic action of roscovitine (ROSC) on human breast cancer MCF-7 cells. We examined the effect of ROSC on cell proliferation, cell cycle progression, nucleolar morphology, posttranslational modifications of histones as well as on induction of apoptosis. The effects of ROSC on the argyrophilic nucleolar organizer regions (AgNORs) and nucleolar RNA of MCF-7 cells were marked: ROSC treatment changed the pattern of AgNORs in a time-dependent manner. The disintegration of nucleoli manifested by increasing number of nucleolar fragments already began at 6 hr posttreatment. This was accompanied by a redistribution of the nucleolin from the nucleolus beginning after 6 hr and preceded a decrease of histone acetylation and phosphorylation. Inhibition of DNA synthesis and accumulation of G(2)/M-arrested cells starting 6 hr posttreatment coincided with a strong increase of the p53 level and with an appearance of a few cells committed to undergo apoptosis. However, all these changes preceded the main wave of apoptosis, which occurred after 24 hr ROSC treatment as assessed by determination of the frequency of Annexin binding, activation of caspases as well as of DNA fragmentation. Onset of PARP-1 cleavage detected by immunoblotting and by immunohistochemistry 6 hr or 9 hr posttreatment, respectively, preceded for a few hours the DNA fragmentation detected in situ by TUNEL assay. Reconstitution of MCF-7 cells with caspase-3 did not change the kinetics of ROSC-induced apoptosis. Our results show that disintegration of nucleoli is an early marker of ROSC-induced changes. Cell cycle arrest precedes the main wave of apoptosis. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845642     DOI: 10.1002/ijc.11290

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  Causes of genome instability: the effect of low dose chemical exposures in modern society.

Authors:  Sabine A S Langie; Gudrun Koppen; Daniel Desaulniers; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Amaya Azqueta; William H Bisson; Dustin G Brown; Gunnar Brunborg; Amelia K Charles; Tao Chen; Annamaria Colacci; Firouz Darroudi; Stefano Forte; Laetitia Gonzalez; Roslida A Hamid; Lisbeth E Knudsen; Luc Leyns; Adela Lopez de Cerain Salsamendi; Lorenzo Memeo; Chiara Mondello; Carmel Mothersill; Ann-Karin Olsen; Sofia Pavanello; Jayadev Raju; Emilio Rojas; Rabindra Roy; Elizabeth P Ryan; Patricia Ostrosky-Wegman; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Frederik J Van Schooten; Mahara Valverde; Jordan Woodrick; Luoping Zhang; Nik van Larebeke; Micheline Kirsch-Volders; Andrew R Collins
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

2.  Gold nanoparticles induce nuclear damage in breast cancer cells, which is further amplified by hyperthermia.

Authors:  Mohamed Kodiha; Eliza Hutter; Sebastien Boridy; Michal Juhas; Dusica Maysinger; Ursula Stochaj
Journal:  Cell Mol Life Sci       Date:  2014-04-17       Impact factor: 9.261

3.  Heat shock protein 70 inhibits hydrogen peroxide-induced nucleolar fragmentation via suppressing cleavage and down-regulation of nucleolin.

Authors:  Kangkai Wang; Gonghua Deng; Guangwen Chen; Meidong Liu; Yuxin Yi; Tubao Yang; Daniel R McMillan; Xiangzhong Xiao
Journal:  Cell Stress Chaperones       Date:  2011-09-30       Impact factor: 3.667

4.  Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.

Authors:  Jolanta D Żołnierczyk; Oxana Komina; Jerzy Z Błoński; Arleta Borowiak; Barbara Cebula-Obrzut; Piotr Smolewski; Paweł Robak; Zofia M Kiliańska; Józefa Węsierska-Gądek
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

5.  CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.

Authors:  Karima Bettayeb; Dianne Baunbæk; Claire Delehouze; Nadège Loaëc; Alison J Hole; Sonja Baumli; Jane A Endicott; Setha Douc-Rasy; Jean Bénard; Nassima Oumata; Hervé Galons; Laurent Meijer
Journal:  Genes Cancer       Date:  2010-04

Review 6.  Targeting bromodomain and extraterminal proteins in breast cancer.

Authors:  Jennifer M Sahni; Ruth A Keri
Journal:  Pharmacol Res       Date:  2017-11-16       Impact factor: 7.658

7.  Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.

Authors:  Mohamed Salah I Abaza; Abdul-Majeed A Bahman; Rajaa J Al-Attiyah
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

8.  Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.

Authors:  Binoj C Nair; Sreeram Vallabhaneni; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Breast Cancer Res       Date:  2011-08-11       Impact factor: 6.466

9.  Selective antitumor activity of roscovitine in head and neck cancer.

Authors:  Cyril Gary; Michael Hajek; Asel Biktasova; Gary Bellinger; Wendell G Yarbrough; Natalia Issaeva
Journal:  Oncotarget       Date:  2016-06-21

10.  Regulation and New Treatment Strategies in Breast Cancer.

Authors:  Rosa-Maria Ferraiuolo; Kay-Uwe Wagner
Journal:  J Life Sci (Westlake Village)       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.